AHA 2024: Featuring The CardioNerds
Novel science and breakthroughs from the American Heart Association’s Scientific Sessions 2024, taking place November 11-13, 2023, in Chicago, IL.
A study shows how how advancements in diagnostic tools and treatments for ATTR-CM have improved risk profiles.
A recent post-hoc analysis of the ATTRibute-CM trial shows the potential for acoramidis in treating ATTR-CM.
The U.S. FDA recently approved Attruby (acoramidis) for adults with ATTR-CM to reduce cardiovascular death, hospitalization.
A study highlights the significant HCRU and costs associated with ATTR-CM.
Promising long-term outcomes from the ongoing OLE of the ATTRibute-CM trial highlight the efficacy of acoramidis.
A case study highlights the importance of avoiding anchoring bias in the diagnosis of cardiac amyloidosis.
The diagnosis of AL amyloidosis requires a high index of suspicion to render a prompt diagnosis and appropriate treatment.
A study further supports the efficacy of acoramidis in the treatment of people with ATTR-CM.
People with amyloidosis have a significantly higher prevalence of atrial fibrillation.
An AI model for detecting ATTR-CA yields solid diagnostic results.
On average, the readability of patient educational materials on cardiac amyloidosis fails to meet NIH standards.
A deep-learning model is able to detect ATTR-CM with robust efficacy.
Practical strategies are needed in health centers to ensure patients with ATTRv receive optimal care.
Artificial intelligence-enhanced ECG models can effectively detect cardiac amyloidosis.
Individuals with transthyretin amyloid cardiomyopathy who have clonal hematopoiesis have an increased risk of mortality.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.